-
Mutual complaints, real-name reports... 10 drugs were processed!
Time of Update: 2022-02-20
For the price correction and price limit rules, Hunan requires three points: First, drugs that have been listed on the Hunan Provincial Pharmaceutical Centralized Purchasing Platform, and the listed price exceeds the lowest unit of the same generic name and the same medical insurance dosage form.
-
Yangzijiang grabs over $1 billion in antithrombotic drug sales growth of 54,767%
Time of Update: 2022-02-20
At present, the xaban products listed in the domestic market include apixaban tablets, rivaroxaban tablets and edoxaban tosylate tablets, of which apixaban tablets and rivaroxaban tablets have been domestically imitated and obtained.
com China's urban physical pharmacy terminal competition Figure 1: Sales of rivaroxaban in the past three years (unit: 100 million yuan) Source: Minet.
-
The newly revised "Class I Medical Device Product Catalog" was announced
Time of Update: 2022-02-20
For products that have been filed before January 1, 2022, the products in accordance with the newly revised "Class I Catalog" are still classified as Class I medical devices.
-
7 functional products will be discontinued immediately, and "health products pit old people" will be sentenced!
Time of Update: 2022-02-20
In order to consolidate the results of the special rectification work in the health food industry, recently, Dalian Market Supervision Bureau launched a special rectification investigation of health food, focusing on four functional health foods such as weight loss, regulation of intestinal flora, promotion of digestion and defecation, focusing on online inspections Whether it is false propaganda, whether it is mixed and sold, whether there is illegal addition, etc.
-
The fifth domestic adalimumab approved!
Time of Update: 2022-02-20
Obviously, as the original research company of adalimumab, the price and market tests that AbbVie faces are only a microcosm of the multinational pharmaceutical companies in China's industrial ecology in the new era .
-
Millennium health resources are exhausted, imports are declining, and prices are brewing!
Time of Update: 2022-02-20
1. Small varieties, limited market attention Yulin market: Millennium Health is a small variety, and the market attention is not high, merchants buy according to demand, the overall supply of goods is general, the market remains stable, and the market price of goods is 28-30 yuan (kg price, The same below), the price changes little in the short term .
-
12 new drugs were approved, and the road of inheritance, innovation and development of traditional Chinese medicine has gone smoothly
Time of Update: 2022-02-20
According to statistics, since 2020, the Center for Drug Evaluation has released more than ten traditional Chinese medicine pharmacology The technical guiding principles and the establishment and improvement of the whole-process quality control system for new traditional Chinese medicines have not only strengthened the guidance for the research and development of enterprises, but also further standardized the review work .
-
The 170 billion market will explode!
Time of Update: 2022-02-20
Under the series of policies, the market concentration of TCM decoction pieces/Traditional Chinese herbal formula granules is expected to increase, and the battle for the leader will become more intense .
-
In the post-epidemic era, the construction of the rehabilitation medicine department of the county hospital has quietly changed
Time of Update: 2022-02-20
In the post-epidemic era, the rehabilitation medicine department of county-level public hospitals urgently needs to strengthen refined management, improve the quality and efficiency of the department, speed up the connotation construction, improve the ability of severe rehabilitation diagnosis and treatment, create special specialties and advantageous disciplines, and play a combination of peace and war.
-
The State Food and Drug Administration revises the instructions for arbidol preparations
Time of Update: 2022-02-20
1. The marketing authorization holders of the above-mentioned drugs should report to the State Drug Administration before April 12, 2022 in accordance with the relevant regulations such as the "Administrative Measures for Drug Registration", and in accordance with the requirements for the revision of the instructions for arbidol preparations (see attachment).
-
Dry eye drug research and development pipeline is hot: who is the "pioneer"?
Time of Update: 2022-02-19
Overall Impression Sales will peak in 2023-2024 According to reports, the global sales of dry eye products in more than 70 major pharmaceutical markets in 2020 will be approximately US$5.
According to the data of Minet, in 2020, the total sales of domestic dry eye medicine public hospitals and retail pharmacies will be 3.
-
The value of the traditional Chinese medicine sector in the capital market is highlighted by the policy of innovation and acceleration
Time of Update: 2022-02-19
The traditional Chinese medicine sector will benefit from logic such as drug price increases in the short term, and will continue to benefit from policy promotion, innovative research and development, and consumption upgrades in the medium and long term .
-
The "14th Five-Year" public service plan released the focus of social medical care!
Time of Update: 2022-02-19
The government supports public welfare social institutions or market entities to increase service supply, improve service quality, and promote key Inclusive development of non-basic public services in the field, so that most citizens can enjoy them at affordable prices .
-
The medical insurance reform goes deeper and the burden on the masses is significantly reduced
Time of Update: 2022-02-19
. Continue to reduce the burden of medical expenses for the masses, normalize and institutionalize the centralized procurement of drugs, and strive to achieve a total of more than 350 drugs in the national and provincial centralized procurement within the year.
-
Hengrui Medicine Nimodipine Oral Liquid is about to be approved and is expected to win the first domestic imitation
Time of Update: 2022-02-19
A few days ago, the official website of the State Food and Drug Administration showed that Jiangsu Hengrui Pharmaceutical's nimodipine oral liquid entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation .
-
70% of rare diseases occur in childhood, multidisciplinary diagnosis and treatment can save lives
Time of Update: 2022-02-19
In terms of multidisciplinary cooperation in diagnosis and treatment of rare diseases, Beijing Children's Hospital, as a national children's medical center, has carried out explorations .
-
The influence, misunderstanding and countermeasures of DRG/DIP
Time of Update: 2022-02-19
Drug companies only look at the impact of DRG/DIP on drugs, and do not consider the impact on device consumables, medical services, and diagnosis and treatment methods.
Therefore, considering the characteristics of DRG/DIP payment methods, the hospital will adjust its business positioning and concentrate resources to develop advantageous departments .
-
China Renaissance Capital's 2021 Annual Review of the Medical and Life Technology Industry｜Pharmaceutical and Biotechnology
Time of Update: 2022-02-17
The notice pointed out that it will focus on frontier biological fields such as brain science, gene editing, synthetic biology, cell therapy, stem cells and regenerative medicine, carry out major scientific and technological research, and promote equipment such as key raw materials, high-end raw and auxiliary materials, important pharmaceutical equipment and consumables, and precision scientific research instruments.
-
Gilead reveals again: $250 million in counterfeit AIDS drugs flowed into the U.S. market
Time of Update: 2022-02-17
In two years, 85,247 bottles of counterfeit versions of the two drugs were sold, worth about $250 million; In the first half of 2021, the Food and Drug Administration investigated and dealt with 3,958 cases of production, sale and use of counterfeit and inferior drugs, worth 38.
-
"Dual Channels" of Medical Insurance: Tibet will include all state-talked drugs; Zhuhai will include 291
Time of Update: 2022-01-27
During the agreement period, all negotiated drugs are included in the "dual-channel" management of our district, and the insured personnel use negotiated drugs in designated medical institutions and designated retail pharmacies, and implement a unified payment policy .
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
